Table 3.
Adverse events | Group | |
---|---|---|
Active | Placebo | |
n = 35 | n = 29 | |
Nausea | 1 (2.9%) | 2 (6.9%) |
Diarrhea | 0 (0%) | 2 (6.9%) |
Constipation | 1 (2.9%) | 1 (3.4%) |
Heartburn | 8 (22.3%) | 3 (10.3%) |
Palpitations | 1 (2.9%) | 0 (0%) |
Daytime sleepiness | 6 (17.1%) | 3 (10.3%) |
Skin lesions | 0 (0%) | 0 (0%) |
Hypoprosexia | 0 (0%) | 1 (3.4%) |
Dysgeusia | 3 (8.6%) | 1 (3.4%) |
Others | 10 (28.6%) | 4 (13.8%) |
Bloated stomach | 5 (14.3%) | 1 (3.4%) |
Abdominal pain | 2 (5.7%) | 0 (0%) |
Early awakening | 1 (2.9%) | 0 (0%) |
Nightmares | 1 (2.9%) | 0 (0%) |
Low libido | 1 (2.9%) | 0 (0%) |
Headache | 0 (0%) | 1 (3.4%) |
Night sweats | 0 (0%) | 1 (3.4%) |
Poorer sleep | 0 (0%) | 1 (3.4%) |
Data are n (%).